Private company

Sorrento Therapeutics

Logo: sorrentotherapeutics.com4

Sorrento Therapeutics is an American biological products company based in San Diego, founded in 2006.1

Last updated Oct 20, 2026.

Overview

2006Founded1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersSan Diego1
  • Websitesorrentotherapeutics.com
  • Incorporated inDE5
  • Business address4955 Directors Place, San Diego, Ca 921215
  • Filer categoryLarge accelerated filer5
  • Legal formCorporation3
  • LEI549300RH23PRR3M134103
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States3
  • Registered withDivision of Corporations, Department of State, 47604193

See how the biggest companies compare on our leaderboards

Sorrento Therapeutics image from its website
Image: sorrentotherapeutics.com4

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-802.6%Operating margin6
-911.6%Net margin6
18.8%Revenue growth, 20226
-$307.5MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Other costs83¢$51.8M
  • Interest14¢$8.6M
  • Income tax4¢$2.4M

Out of $62.8M in revenue.6 The company lost money this year.

Financial statements

Revenue7896$62.8M in 2022+671% since 2016
0$50.0M$100.0M$150.0M$200.0M2016: $8.2M$8.2M20162017: $151.9M$151.9M2017+1763%2018: $21.2M$21.2M2018−86%2019: $31.4M$31.4M2019+48%2020: $40.0M$40.0M2020+27%2021: $52.9M$52.9M2021+32%2022: $62.8M$62.8M2022+19%
Operating income8910116-$504.3M in 2022+421% since 2016
-$600.0M-$400.0M-$200.0M0$200.0M2016: -$96.8M-$96.8M20162017: $25.3M$25.3M20172018: -$150.4M-$150.4M20182019: -$259.4M-$259.4M2019+72%2020: -$244.5M-$244.5M2020−6%2021: -$401.5M-$401.5M2021+64%2022: -$504.3M-$504.3M2022+26%
Net income8910116-$572.8M in 2022+840% since 2016
-$600.0M-$400.0M-$200.0M0$200.0M2016: -$60.9M-$60.9M20162017: $9.1M$9.1M20172018: -$203.5M-$203.5M20182019: -$292.1M-$292.1M2019+43%2020: -$298.5M-$298.5M2020+2%2021: -$428.3M-$428.3M2021+44%2022: -$572.8M-$572.8M2022+34%
Fiscal year2016201720182019202020212022
Revenue$8.2M7$151.9M8$21.2M9$31.4M9$40.0M6$52.9M6$62.8M6
Cost of revenue$811.0K8$3.9M8$7.1M8
Research and development$45.0M8$26.1M8$11.3M8
Operating expenses$454.4M6$567.2M6
Operating income-$96.8M8$25.3M9-$150.4M10-$259.4M11-$244.5M6-$401.5M6-$504.3M6
Interest$1.6M8$5.0M9$57.6M10$35.0M11$20.2M6$10.2M6$8.6M6
Income before tax-$462.7M6-$580.2M6
Income tax-$896.0K8-$36.0M9-$6.3M10-$473.0K11-$2.0M6-$33.5M6-$2.4M6
Net income-$60.9M8$9.1M9-$203.5M10-$292.1M11-$298.5M6-$428.3M6-$572.8M6
Earnings per share-$1.218$0.139-$1.9210-$2.2011-$1.306-$1.456-$1.376
Earnings per share (diluted)-$1.218$0.139-$1.9210-$2.3511-$1.306-$1.456-$1.376
Shares (weighted, basic)294.8M shares6419.3M shares6
Shares (weighted, diluted)294.8M shares6419.3M shares6

Compare Sorrento Therapeutics with another company

Corporate structure

Sorrento Therapeutics sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Sorrento Therapeutics

  • State Street Corporation Filed SC 13G/A on Sorrento Therapeutics, latest Mar 10, 2023 (3 filings since Jul 11, 2022)
  • ICS OPPORTUNITIES, LTD. Filed SC 13G on Sorrento Therapeutics, latest Feb 17, 2023
  • VANGUARD GROUP INC Filed SC 13G/A on Sorrento Therapeutics, latest Feb 9, 2023 (2 filings since Feb 10, 2022)
  • Sorrento Therapeutics Wilmington, Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Sorrento Therapeutics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$103.4M6 Dec 31, 2022$84.8M6 Dec 31, 2021+21.9%
Accumulated depreciation$51.4M6 Dec 31, 2022$43.5M6 Dec 31, 2021+18.2%
Property and equipment, net$52.0M6 Dec 31, 2022$41.3M6 Dec 31, 2021+25.8%
Operating-lease assets (leased space)$86.5M6 Dec 31, 2022$85.2M6 Dec 31, 2021+1.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$23.6M6 Dec 31, 2022$36.7M6 Dec 31, 2021−35.5%
Marketable securities, current$26.3M6 Dec 31, 2022$90.2M6 Dec 31, 2021−70.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$80.3M6 Dec 31, 2022$79.5M6 Dec 31, 2021+0.9%
Intangible assets, net (excluding goodwill)$136.9M6 Dec 31, 2022$259.7M6 Dec 31, 2021−47.3%
Finite-lived intangibles, gross$160.7M6 Dec 31, 2022$279.2M6 Dec 31, 2021−42.4%
Accumulated amortization$23.8M6 Dec 31, 2022$19.5M6 Dec 31, 2021+22.2%
Finite-lived intangibles, net$42.7M6 Dec 31, 2022$41.3M11 Dec 31, 2021+3.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$10.0M6 Dec 31, 2022$8.1M6 Dec 31, 2021+23.1%
Finished goods$3.4M6 Dec 31, 2022$4.7M6 Dec 31, 2021−27.7%

Leadership

Who has led Sorrento Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Kevin R. Keating2007
  2. Glenn L. Halpryn2008
  3. Antonius Schuh2009–2010
  4. Henry Ji2012–2017

Chair

  1. Antonius Schuh2010

President

  1. Glenn L. Halpryn2008
  2. Henry Ji2013–2017

Chief financial officer

  1. Kevin R. Keating2007
  2. Alan Jay Weisberg2008
  3. Richard G. Vincent2010–2013
  4. Mark Durand2015
  5. Kevin Herde2016–2017
  6. Jiong Shao2018–2020
  7. Najjam Asghar2020–2021
  8. Elizabeth Czerepak2022

Chief operating officer

  1. Jeffrey Su2015–2017
2010201520202025
Board members and other officers (44)

Former names

  • QUIKBYTE SOFTWARE INCJul 14, 2006 to Nov 12, 20095

Timeline

  1. Nov 7, 20238-K Executive or director change; Other events65
  2. Nov 3, 20238-K Entered a material agreement; Completed an acquisition or sale66
  3. Oct 27, 20238-K Executive or director change67
  4. Oct 5, 20238-K Entered a material agreement68
  5. Sep 26, 20238-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale69
  6. Sep 13, 20238-K Other events70
  7. Aug 28, 20238-K Entered a material agreement; Other events71
  8. Aug 21, 20238-K Regulation FD disclosure72
  9. Aug 10, 20238-K Entered a material agreement; New debt or obligation; Regulation FD disclosure73
  10. Aug 1, 20238-K Regulation FD disclosure74
  11. Jul 13, 20238-K Regulation FD disclosure75
  12. Jul 10, 20238-K Entered a material agreement; New debt or obligation76
  13. Feb 7, 2012New chief executive Henry Ji becomes CEO14
  14. Sep 23, 2009New chief executive Antonius Schuh becomes CEO15
  15. Jul 7, 2008New chief executive Glenn L. Halpryn becomes CEO16
  16. Mar 26, 2007New chief executive Kevin R. Keating becomes CEO17
  17. 2006Founded Founded1

Calendar

When it reported results

  1. Apr 4, 2022Reported quarterly or annual results77

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

127 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 66 major events, 16 insider forms, 9 large holders, 28 other. The latest 20:

  1. Feb 21, 2025SEC STAFF ACTION EDGAR
  2. Nov 7, 20238-K EDGAR
  3. Nov 3, 20238-K EDGAR
  4. Oct 27, 20238-K EDGAR
  5. Oct 5, 20238-K EDGAR
  6. Sep 26, 20238-K EDGAR
  7. Sep 13, 20238-K EDGAR
  8. Aug 28, 20238-K EDGAR
  9. Aug 21, 20238-K EDGAR
  10. Aug 14, 202310-Q EDGAR
  11. Aug 10, 20238-K EDGAR
  12. Aug 7, 2023NT 10-Q EDGAR
  13. Aug 1, 20238-K EDGAR
  14. Jul 18, 2023POS AM EDGAR
  15. Jul 13, 20238-K EDGAR
  16. Jul 10, 20238-K EDGAR
  17. Jun 21, 2023POS AM EDGAR
  18. Jun 20, 20238-K EDGAR
  19. Jun 15, 20238-K EDGAR
  20. May 19, 20238-K EDGAR

The 127 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 5 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 7, 2022Ji HenrySee RemarksBuy88,888$2.02$179.6KForm 4
Sep 6, 2022Ji HenrySee RemarksBuy55,555$1.96$108.9KForm 4
Aug 26, 2022Ji HenrySee RemarksBuy33,333$2.11$70.3KForm 4
Aug 25, 2022Ji HenrySee RemarksBuy22,222$2.06$45.8KForm 4
Jun 14, 2022Ji HenrySee RemarksBuy10,000$1.40$14.0KForm 4
Dec 27, 2021Janda KimDirectorSale3,000$5.88$17.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Sorrento Therapeutics is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSorrento Therapeutics, Inc.2
  • CIK0000850261
  • Employer ID (EIN)33-03448422
  • Filer statusLarge accelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address4955 Directors Place, San Diego, CA 921212
  • Phone858-203-41002
  • Shares outstanding551,281,154 as of Aug 8, 202313
  • Public float$856.3M as of Jun 30, 20226
  • On EDGAR sinceJul 14, 20062
  • Filings1,163 in all: 8-K (329), 4 (261), 3 (62), 10-Q (47), CORRESP (38), UPLOAD (36), SC 13G/A (35), SC 13G (32)2
    All 57 form types

    SC 13D/A (28), 424B3 (24), EFFECT (22), S-3 (22), CT ORDER (19), 424B5 (17), 10-K (15), S-3/A (14), DEF 14A (13), SC 13D (13), 10QSB (12), 4/A (9), 8-K/A (9), S-8 (9), 10-K/A (8), DEFA14A (8), NT 10-Q (8), PRE 14A (7), 10-Q/A (6), 10KSB (6), D (5), NT 10-K (5), 425 (4), SEC STAFF LETTER (4), 3/A (3), 5 (3), POS AM (3), SC 14F1 (3), SC 14F1/A (3), 8-A12B (2), 10QSB/A (1), 25-NSE (1), 424B2 (1), 424B7 (1), 5/A (1), 8-A12G (1), 8-A12G/A (1), CERTNAS (1), DEF 14C (1), DEFN14A (1), DEFR14A (1), DFAN14A (1), FWP (1), PRE 14C (1), PREN14A (1), PRER14A (1), PRRN14A (1), S-3ASR (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (10-K) Mar 16, 2023
    Quarterly report (10-Q) Aug 14, 2023
    Proxy statement (DEF 14A) Nov 1, 2022
    Latest 8-K (8-K) Nov 7, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
    SEC EDGAROther events
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80